BriaCell Therapeutics Corp. Warrant (BCTXW)

Etorro trading 970x250

About BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1

BriaCell Therapeutics Corp. Warrant News and around…

Latest news about BriaCell Therapeutics Corp. Warrant (BCTXW) common stock and company :

October is Breast Cancer Awareness Month – BriaCell is Advancing the Fight with its Immunotherapy
05 Oct, 2021 Yahoo! Finance

BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, acknowledges that October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer support, prevention, detection, diagnosis, trea

BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com
23 Sep, 2021 FinancialContent
BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid
22 Sep, 2021 FinancialContent
BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30
16 Sep, 2021 FinancialContent
BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants
09 Sep, 2021 FinancialContent
BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors
01 Sep, 2021 FinancialContent
BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
23 Aug, 2021 FinancialContent
BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer
19 Aug, 2021 FinancialContent

BriaCell to utilize ImaginAb’s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells

Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
16 Aug, 2021 Yahoo! Finance

LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience.The SNN Network Summer Virtual Event begins on Tuesday, August 17, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders, incl

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment
14 Jul, 2021 FinancialContent
BriaCell to Present at Three Upcoming Investor Conferences
12 Jul, 2021 FinancialContent
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
08 Jul, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th \- 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers
16 Jun, 2021 FinancialContent
BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises
10 Jun, 2021 FinancialContent

Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET
09 Jun, 2021 FinancialContent
BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement
07 Jun, 2021 FinancialContent
BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement
03 Jun, 2021 FinancialContent
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
02 Jun, 2021 FinancialContent
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
19 May, 2021 FinancialContent
BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
11 May, 2021 FinancialContent
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
21 Apr, 2021 FinancialContent
BriaCell Announces Investor and Media Outreach Programs
15 Apr, 2021 FinancialContent
BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million
12 Apr, 2021 FinancialContent
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
12 Apr, 2021 FinancialContent
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
30 Mar, 2021 FinancialContent
BriaCell Announces Closing of US$25 Million Public Offering
26 Feb, 2021 FinancialContent

BriaCell Therapeutics Corp. Warrant (BCTXW) is a NASDAQ Common Stock listed in

970x250